The C2min aptamer-modified gene delivery system for targeting ADPC/AIPC prostate cancer
10.3969/j.issn.1006-0111.201906038
- VernacularTitle:适配体C2min介导的可靶向2种前列腺癌基因的递送系统
- Author:
Jing ZHANG
1
;
Yongwei GU
2
;
Xin WU
3
,
4
Author Information
1. Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China.
2. Shanghai Wei Er Laboratory, shanghai 201712, China.
3. Department of Pharmacy, Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010050, China
4. Shanghai Wei Er Laboratory, shanghai 201712, China.wuxin007@126.com
- Keywords:
adapter;
targeting drug delivery;
androgen-dependent prostate cancer;
androgen-independent prostate cancer;
gene vector
- From:
Journal of Pharmaceutical Practice
2020;38(1):47-51
- CountryChina
- Language:Chinese
-
Abstract:
Objective To synthesize a novel prostate cancer targeting gene vector PAMAM-PEG-C2min and improve gene transfection efficiency targeting on prostate cancer. Methods The aptamer (C2min) and polyamide-amine (PAMAM) were ligated by polyethylene glycol (PEG). The structure of the synthesized PAMAM-PEG-C2min was identified by NMR. The biological characteristics of the nanoparticles were examined by the uptake experiments and gene transfection experiments (the loaded gene was siR-M) with the prostate cancer cells (PC3 and LNCaP). Besides, the in vivo targeting was investigated using in vivo image system. The in vivo targeting results indicated that PAMAM-PEG-C2min can achieve the simultaneous targeting of two prostate cancer tissues. Results The PAMAM-PEG-C2min synthesis was confirmed by NMR. Cell uptake experiments showed that the cell uptake efficiency of PAMAM-PEG-C2min was concentration dependent. In vitro experiments showed that the PC3 and LNCaP cells transfection efficiency and targeting of PAMAM-PEG modified with C2min were significantly improved compared with the PEG modified PAMAM. Conclusion PAMAM-PEG-C2min is a potential targeted drug delivery vehicle. It provides a new technology platform for comprehensive and specific targeting treatment of prostate cancer.
